Stockreport

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

VistaGen Therapeutics, Inc.  (VTGN) 
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vistagen.com
PDF Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing with ongoing PALISADE-3, PALISADE-4 and Repeat [Read more]